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Associations between SLC16A11 
variants and diabetes in the 
Hispanic Community Health study/
study of Latinos (HCHs/soL)
Bertha A. Hidalgo1, tamar sofer  2, Qibin Qi3, Neil schneiderman4, Y.-D. Ida Chen5, Robert 
C. Kaplan3,11, M. Larissa Avilés-santa6, Kari e. North7, Donna K. Arnett8, Adam szpiro9, 
Jianwen Cai10, Bing Yu12, eric Boerwinkle12, George papanicolaou6, Cathy C. Laurie9, 
Jerome I. Rotter5 & Adrienne M. stilp9
Five sequence variants in SLC16A11 (rs117767867, rs13342692, rs13342232, rs75418188, and 
rs75493593), which occur in two non-reference haplotypes, were recently shown to be associated with 
diabetes in Mexicans from the sIGMA consortium. We aimed to determine whether these previous 
findings would replicate in the HCHS/SOL Mexican origin group and whether genotypic effects were 
similar in other HCHS/SOL groups. We analyzed these five variants in 2492 diabetes cases and 5236 
controls from the Hispanic Community Health study/study of Latinos (HCHs/soL), which includes 
U.s. participants from six diverse background groups (Mainland groups: Mexican, Central American, 
and south American; and Caribbean groups: puerto Rican, Cuban, and Dominican). We estimated 
the sNp-diabetes association in the six groups and in the combined sample. We found that the risk 
alleles occur in two non-reference haplotypes in HCHs/soL, as in the sIGMA Mexicans. the haplotype 
frequencies were very similar between sIGMA Mexicans and the HCHs/soL Mainland groups, but 
different in the Caribbean groups. The SLC16A11 sequence variants were significantly associated with 
risk for diabetes in the Mexican origin group (p = 0.025), replicating the SIGMA findings. However, 
these variants were not significantly associated with diabetes in a combined analysis of all groups, 
although the power to detect such effects was 85% (assuming homogeneity of effects among the 
groups). Additional analyses performed separately in each of the five non-Mexican origin groups were 
not significant. We also analyzed (1) exclusion of young controls and, (2) SNP by BMI interactions, but 
neither was significant in the HCHS/SOL data. The previously reported effects of SLC16A11 variants 
on diabetes in Mexican samples was replicated in a large Mexican-American sample, but these effects 
were not significant in five non-Mexican Hispanic/Latino groups sampled from U.S. populations. Lack 
of replication in the HCHs/soL non-Mexicans, and in the entire HCHs/soL sample combined may 
represent underlying genetic heterogeneity. these results indicate a need for future genetic research to 
consider heterogeneity of the Hispanic/Latino population in the assessment of disease risk, but add to 
the evidence suggesting SLC16A11 as a potential therapeutic target for type 2 diabetes.
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Hispanics/Latinos represent the largest ethnic minority population in the United States1. They are a diverse group 
of individuals, varying greatly from one another genetically, socially, economically, and culturally, despite usually 
being classified as a single ethnic group. In particular, variation in the prevalence of diabetes among Hispanic/
Latino groups2 indicates that specific Hispanic/Latino background should be considered in genetic and other 
analyses.
SLC16A11 is a member of the solute carrier family 16, which appears to be involved in hepatic lipid metab-
olism3. Williams et al. reported an SLC16A11 haplotype, defined by 5 single nucleotide polymorphisms (SNPs), 
as a common risk factor for diabetes in Mexican and Mexican-American populations studied by the SIGMA 
consortium3. Four of the five variants are missense SNPs, and the frequency of the risk haplotype is high (~50%) 
in Hispanics/Latinos with high Native American ancestry but rare or absent in people of European and African 
ancestry. Results from the discovery sample were replicated in a meta-analysis of several multi-ethnic popula-
tions, in which most of the evidence appeared to come from Native Hawaiian, East Asian and Mexican American 
samples.
Here, we examined the SNP associations with diabetes reported by Williams et al., in U.S. Hispanics/Latinos 
from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), which includes individuals who 
self-identified as having Mexican, Central American, South American, Puerto Rican, Dominican or Cuban back-
ground or heritage (Table 1). We assessed whether the associations of the five SNPs with diabetes status were 
observed in each of these groups and whether there is evidence of group-specific effects. In addition, we tested these 
five SNPs for interaction with obesity in their effects on diabetes to test associations described by Traurig et al.4, 
as described below.
Methods
study sample. HCHS/SOL is a multicenter community–based cohort study of Hispanic/Latino populations 
in the United States, previously described5,6. Of the 12,803 individuals successfully genotyped in SOL, 428 did 
not self-identify as one of the six specific background groups. The 428 exceptions either had missing, multiple or 
‘other’ background. These 428 individuals were not outliers with respect to the entire sample set. PCs indicated 
that some individuals were outliers with respect to their self-identified group, but not with respect to other back-
grounds. Therefore, six ‘genetic analysis groups’ using both self-identified background and principal components 
so that all individuals would be included in the specific background group and to improve the genetic homoge-
neity within those groups, were included in these analyses. The analyses described here therefore included 2,492 
individuals with diabetes and 5,236 controls, for a total of 7,728 individuals, with demographic and diabetic char-
acteristics shown in Table 1. The study was conducted with the approval of the Ethics and Institutional Review 
Boards of all institutions involved (i.e., Bronx Field Center – Albert Einstein School of Medicine; Chicago Field 
Center – University of Illinois Chicago; Miami Field Center – University of Miami; San Diego Field Center – San 
Diego State University), and informed consent was obtained from all participants. HCHS/SOL was conducted 
under the oversight of each institutional review board (IRB) at the field centers and coordinating center institu-
tions, http://www.cscc.unc.edu/hchs. HCHS/SOL had an Observational Studies Monitoring Board that served as 
advisory to the NHLBI and provided oversight on participant burden, safety, study progress. Further, all methods 
were performed in accordance with the relevant guidelines and regulations.
Definition of Diabetic Status. In accordance with the American Diabetes Association (ADA)7, individuals 
with diabetes were defined as those with fasting time >8 hours and fasting glucose levels ≥126 mg/dL; or fasting 
≤8 hours and fasting glucose ≥200 mg/dL; or post-oral glucose tolerance test (OGTT) glucose ≥200 mg/dL; or 
hemoglobin A1C (HbA1C) ≥6.5%; or if on current treatment with a hypoglycemic agent. Controls with normal 
glucose tolerance were defined as anyone with fasting time >8 hours and fasting glucose levels less than 100 mg/
dL; and post-OGTT glucose less than 140 mg/dL; and HbA1C less than 5.6%. Individuals with pre-diabetes inter-
mediate phenotypes were excluded from this analysis. We were unable to cleanly separate T2D from T1D for the 
Group N Age (SD) Male, % BMI (SD) Fasting glucose (SD)
All
Controls 5236 38.9 (13.4) 39.6 28.1 (5.6) 89.7 (5.7)
Cases 2492 55.0 (10.3) 39.8 31.2 (6.5) 149.2 (64.0)
Dominican
Controls 523 37.3 (13.4) 32.9 28.1 (5.5) 88.7 (5.7)
Cases 217 55.9 (10.3) 35.0 31.3 (6.2) 139.8 (57.0)
Mexican
Controls 1914 37.9 (13.5) 38.5 28.1 (5.4) 89.6 (5.7)
Cases 965 52.8 (10.7) 39.1 32.0 (6.2) 151.5 (66.0)
Puerto Rican
Controls 840 38.9 (13.9) 42.4 28.9 (6.5) 89.0 (5.9)
Cases 557 56.7 (10.2) 39.3 33.4 (7.1) 148.6 (61.6)
Cuban
Controls 918 42.3 (13.3) 41.5 27.7 (5.5) 90.3 (5.7)
Cases 396 57.9 (9.2) 47.2 31.7 (6.2) 149.9 (65.9)
South American
Controls 450 40.0 (12.8) 39.6 27.1 (4.6) 90.1 (5.7)
Cases 113 56.2 (9.2) 34.5 31.5 (6.1) 137.5 (54.2)
Central American
Controls 591 37.9 (12.5) 42.0 28.4 (5.4) 90.3 (5.4)
Cases 244 54.2 (9.2) 38.9 32.1 (6.1) 154.3 (67.6)
Table 1. Demographics for cases and controls in HCHS/SOL.
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sample included in this analysis because T1D is largely an autoimmune disease identified by at least one diabetes 
autoantibody (glutamic acid decarboxylase or insulinoma associated antibody)8 and these measures were not 
assessed in HCHS/SOL. Furthermore, studies show that the age of onset of T2D has substantially decreased in the 
last few years, so that age at diagnosis could not be used to distinguish between diabetes types9,10. In any case, it 
seems unlikely that results will be affected substantially by not making the type 1 versus type 2 distinction, given 
that within our HCHS/SOL sample, only 9 individuals in our sample aged 18–29 years could potentially have 
T1D based on use of insulin2 and all participants used in this analysis were greater than 18 years of age. Among 
those, 3 were Dominican, 1 Central American, 4 Mexican, and 1 Puerto Rican. Finally, the prevalence of T1D 
in the United States was estimated to be only 4.3% in 2012, further indicating the low prevalence of individuals 
with type 1 diabetes in the general population7.
Genotyping and imputation. Genotyping was performed with an Illumina custom array (15041502 B3), 
which consists of the Illumina Omni 2.5 M array (HumanOmni2.5-8v1-1) plus approximately 150k custom SNPs. 
QA/QC methods have been previously described11,12. Genome-wide imputation was carried out using the 1000 
Genomes Project phase 1 reference panel13, SHAPEIT212 and IMPUTE2 software14, as described previously12.
Relatedness, population structure, and genetic analysis groups. Kinship coefficients and principal 
components were estimated using PC-Relate12. Genetic analysis groups were constructed based on a combination 
of self-identified Hispanic/Latino background and genetic similarity, and are classified as Cuban, Dominican, 
and Puerto Rican (Caribbean groups); and Mexican, Central American, and South American (Mainland groups). 
The genetic analysis groups largely overlap with the self-identified background groups, but using the genetic 
analysis groups in association testing and stratified analyses has advantages as shown by Conomos et al.12. Briefly, 
Conomos et al., showed that using genetic analysis group (as we did in this analysis and manuscript), rather than a 
self-identified background group “achieved higher power to detect previously reported associations”. The average 
proportions of three continental ancestries (European, African and Native American) differ among these groups, 
with Caribbean groups having more African and less Native American ancestry than the Mainland groups12.
Haplotype frequency estimation. Genotypes for the five SNPs constituting the risk haplotype defined by 
the SIGMA consortium are either assayed on the array or very well imputed (imputation “info” score >0.99) in 
HCHS/SOL (Table 2). To confirm imputation quality, we also performed both a Spearman correlation analysis as 
well as a genotype comparison between the data used in this analysis and the HCHS/SOL whole genome sequence 
(WGS) data, wherein we found that the concordance between the two platforms was high – all SNPS had a 
correlation coefficient greater than 0.99. There were only a handful of mismatches between SNPs measured and 
those imputed, which even if confined to one group, would not represent substantial inaccuracy in imputation. 
In HCHS/SOL, these five SNPs formed the same three haplotypes as seen in the Williams et al. study (Fig. 1). The 
minor alleles of the five SNPs may appear together to form the 5-SNP haplotype, or the minor alleles of only two 
of the SNPs (rs13342232 and rs13342692; “LD group 1”) may appear with the reference alleles of the other three 
SNPs (rs75493593, rs75418188, and rs117767867; “LD group 2”) to form the 2-SNP haplotype. The SNPs within 
each of the two LD groups are highly correlated (r2 > 0.99). Therefore, we estimated haplotype frequencies as in 
Williams et al.3 the 5-SNP haplotype as the frequency of the minor allele of a given SNP from LD group 2, and the 
frequency of the 2-SNP haplotype as the frequency of the major allele of a given SNP from LD group 1 minus the 
frequency of a given SNP from the 5-SNP haplotype.
power analysis. We calculated power for replicating the association reported by Williams et al.3 for 
rs75493593. We considered replication in the Mexican group, other individual groups, and the combined analysis 
of all HCHS/SOL analysis participants. To avoid a potential bias in the odds ratio (OR) estimation due to the win-
ner’s curse, we used OR = 1.20 (95%CI = 1.09–1.31) as estimated in the replication study of Williams et al., rather 
than the discovery estimate of OR = 1.29. We calculated power following15, assuming a significance level of 0.025 
(for testing two haplotypes), as described further in Supplementary Material.
SNP
Inferred haplotypes
chr17: position Amino Acid LD group* TypeReference 2-SNP 5-SNP
rs75493593 G G T 6945087 P443T 2 Imputed (r2 = 99.9)
rs75418188 C C T 6945483 G340S 2 Imputed (r2 = 99.9)
rs13342232 A G G 6945940 L187L 1 genotyped
rs13342692 T C C 6946287 D127G 1 genotyped
rs117767867 C C T 6946330 V113I 2 Imputed (r2 = 99.8)
Table 2. Haplotype structure of five coding sequence variants in the SLC16A11 gene and their estimated 
frequencies. *LD group: linkage disequilibrium between SNP pairs within each of the two groups in HCHS/
SOL is r2 > 0.99, while r2 values for SNP pairs between groups varies among groups (0.75 for Central American, 
0.89 for Mexican, 0.85 for South American, 0.37 for Cuban, 0.11 for Dominican and 0.33 for South American 
groups).
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statistical analysis. Our association analyses focused on the 5-SNPs haplotype reported in Williams et al. 
Because this haplotype is tagged by the minor allele of rs75493593, we report association analyses results for 
this SNP. Rs75493593-diabetes association analysis was performed using GMMAT16, which is based on a logis-
tic penalized quasi-likelihood (PQL) model that approximates the logistic generalized linear mixed model. 
Correlations between the HCHS/SOL participants were accounted for by incorporating covariance matrices cor-
responding to genetic relatedness (kinship), household, and census block group as random effects. The model 
included center, age, sex, log10 BMI, the first five principal components to adjust for ancestry, and sampling 
weights17. To study how diabetes associations with rs75493593 vary by genetic analysis group, we included 
statistical interaction terms in the model. The PQL also estimated the covariance between the group-specific 
effect estimates. We then obtained pooled estimates of the genotype effect estimates, as well as the Cochran 
Q test of heterogeneity, using MetaCor18, which accounts for correlations between group-specific effect esti-
mates (see Supplementary Material). Results for each of the specific SNPs in the haplotype are provided in the 
Supplementary Material.
Results
SLC16A11 SNPs and Haplotypes. While the haplotype structure reported in Williams et al.3 also exists 
in the HCHS/SOL, the haplotype frequencies varied across genetic analysis groups (Table 3). In the Mexican, 
Central and South American groups, the haplotype frequencies were similar to those in the SIGMA Mexicans. 
In the three Caribbean groups, the frequencies of the 5-SNP haplotype were substantially lower than in the three 
Mainland groups, as expected because this haplotype appears to be largely specific to Amerindian ancestry, which 
is low in Caribbean groups12. In addition, the 2-SNP haplotype, which is largely specific to African ancestry, 
occurred at higher frequency in the Caribbean than in the Mainland groups, as expected because African ances-
try is low in Mainland groups12.
Figure 1. SLC16A11 haplotypes in HCHS/SOL. The lower panel shows the reference haplotypes, with the 
reference (major) alleles for all 5 SNPs. The 2-SNP haplotype is composed of the non-reference (minor) alleles 
of the two blue SNPs, with the reference alleles for the other three SNPs. The 5-SNP haplotype has non-reference 
alleles for all 5 SNPs. The blue SNPs are LD group 1, and the red SNPs are LD group 2.
Haplotype frequency estimates**
Reference 2-SNP 5-SNP
SIGMA Mexican 0.68 0.02 0.30
HCHS/SOL
Mexican 0.70 0.02 0.28
Central American 0.73 0.05 0.22
South American 0.73 0.03 0.24
Cuban 0.90 0.06 0.04
Dominican 0.80 0.17 0.03
Puerto Rican 0.82 0.11 0.07
1000G phase 3
AFR 0.62 0.38 0.00
AMR 0.72 0.03 0.24
EAS 0.90 0.00 0.10
EUR 0.98 0.01 0.01
SAS 0.99 0.00 0.00
Table 3. Estimated frequencies of inferred haplotypes. **Haplotype frequency estimates for HCHS/SOL were 
derived from unphased genotypes (as described in Methods); for 1000 G, they were calculated directly from 
phased genotypes. Listed in same order as haplotypes above.
www.nature.com/scientificreports/
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Rs75493593 Associations with Diabetes Status. The expected power to replicate the 5-SNP haplo-
type, tagged by rs75493593, effect on diabetes status was 0.85 for all groups combined, 0.55 for the Mexican 
group, and 0.04 to 0.14 for each of the other genetic analysis groups (assuming a homogeneous effect with 
OR = 1.20; see Supplementary Material). The SNP effect estimates for the Mexican group were all directionally 
consistent with those reported in the Williams’ paper, and four of the five SNPs replicated (one-sided p = 0.025; 
Supplementary Material). The odds ratio estimate for the top SNP rs75493593 in the HCHS/SOL Mexican group 
was 1.17 (CI: 1.00–1.37, p = 0.025), compared with OR = 1.29 (95% CI: 1.20–1.38) in the SIGMA discovery and 
OR = 1.20 (95% CI: 1.09–1.31) in the SIGMA replication set. The effect estimates in each of the non-Mexican 
groups are in the opposite direction from the effect estimate for the Mexican background group but are not sig-
nificant, although the test for heterogeneity among the groups is suggestive of possible heterogeneity (p = 0.07; 
Supplementary Material; Fig. 2). In a meta-analysis of all groups, the association of SLC16A11 variants with 
diabetes was not significant (p = 0.27).
We repeated these association tests after excluding controls <45 years old (3436 participants) to better approx-
imate the control definitions used in some of the Williams et al. sample sets. The results are qualitatively similar to 
the full sample set, but no SNPs are statistically significant in any group, likely due to less power from the smaller 
sample set (see Supplementary Material).
Previously, Traurig et al.4 reported that the 5-SNP haplotype in a Native North American sample has a sig-
nificant interaction with obesity, such that the rs75493593 risk allele (marking the 5-SNP haplotype) has a pos-
itive effect estimate in individuals with low body mass index (BMI), while having a negative effect estimate in 
those with high BMI. Such a relationship could explain the apparent heterogeneity in effect estimates among the 
HCHS/SOL groups if a similar interaction occurs in these populations and if the Mexican group has lower BMI. 
However, neither one of these conditions was observed (see Supplementary Material).
Discussion
The initial SIGMA discovery of an association between SLC16A11 and diabetes was from a GWAS of Mexicans 
and Mexican-Americans, with replication through meta-analysis of a set of cohorts of diverse ancestries3. In 
HCHS/SOL, we found that the 5-SNP haplotype is significantly associated with diabetes in participants of 
Mexican background (p = 0.025), with the same direction of effect as in SIGMA. However, the association is not 
significant in the HCHS/SOL cohort as a whole (despite 85% power to detect a significant effect), nor is it signifi-
cant within any of the other five Hispanic/Latino background groups. We also observed that the 95% confidence 
intervals in each of the subgroups include the point estimate for the positive association in Mexicans, even if not 
significant. Thus, while non-replication of the effect in any specific group could be explained by lack of power, the 
power was high in the combined analysis. In fact, the effect estimates for the five non-Mexican groups are consist-
ently in the opposite direction of the effect in the Mexican group. A test of SNP-by-group interaction has a P-value 
of 0.07, further suggesting not only the heterogeneity of effect among these diverse Hispanic/Latino groups, but 
providing further evidence of the specificity of SLC16A11 in Mexican-origin populations.
The estimated effects between the HCHS/SOL Mexicans and the other groups is unexpected, given that allelic 
and haplotypic frequencies are very similar among the HCHS/SOL Central American, South American and 
Mexican groups. Furthermore, the Williams et al. study generalized their initial finding in Mexicans to diverse 
populations, including East Asians. One might expect that a finding in Mexicans that generalizes to East Asians, 
should also generalize to other Hispanic/Latino populations more similar to Mexicans, such as Central and 
South Americans. We further hypothesized that this apparent heterogeneity among HCHS/SOL groups might 
be caused by differing age or BMI distributions, but the results of these analyses did not reveal more insights (see 
Supplementary Material). We speculate that the variation among groups might be due to variation in pattern 
of LD with the causal variant(s), interactions with other genetic variants that differentiate the groups, or with 
non-genetic differences among the groups. It is unlikely that an LD plot of this region would not have provided 
much clarity, or that it would have demonstrated a significant difference between groups. Another possibility is 
simply that the predicted high power to detect an overall effect in the HCHS/SOL cohort was not realized due to 
un-modeled sources of variability or residual confounding.
In this study, we chose to limit our analyses to the SLC16A11 variants, however have explored other 
T2D-associated variants in HCHS/SOL elsewhere19. Other studies have also examined the replication of the 
Figure 2. Summary results for association analysis of rs75493593, which tags the 5-SNP haplotype, with 
diabetes in the HCHS/SOL. Odds ratio estimates and their 95% confidence intervals are given in the Forest 
plots. Risk “AF” refers to risk allele frequency. “Summary” gives meta-analysis results. The meta-analysis 
replication (one-sided) p-value was 0.28, while the replication p-value in Mexicans was 0.025.
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Williams et al. result in related populations. Traurig, et al. also found that the 5-SNP haplotype is significantly 
associated with diabetes in a sample of 12,811 Native North Americans, with an effect dependent on BMI4. Others 
have investigated the role of one of the five variants in a sample of 575 Mayan individuals from Mexico, finding 
that rs13342692 was not significantly associated with diabetes after adjustment for BMI20, but given the small 
sample the lack of replication may be due simply to low power. Recent SLC16A11 functional work in individuals 
of Mexican origin by Rusu, et al. suggests that T2D disrupts gene function at this locus and could be a therapeutic 
target for this population. We performed an LD analysis of these new sequence variants in our data and found that 
the LD between the 5 SNPs in our study and the new SNPs in the Rusu et al. paper is high (r2 > 0.85), as expected. 
Rusu, et al. reported 13 new SNPs, and we discussed the additional 5 SNPs in this paper. Of those, 11 SNPs were 
in our imputed data and in high LD with the variants in our LD group 2; 8 of them had LD > 0.98 and the other 
3 had LD > 0.85, further supporting our Mexican-origin specific findings21. Our HCHS/SOL results contribute 
to understanding the genetic underpinnings of diabetes in Mexicans, indicate a need for future genetic research 
to consider heterogeneity of the Hispanic/Latino population in the assessment of disease risk, and provides addi-
tional evidence suggesting that SLC16A11 could be a therapeutic target for T2D.
Data Availability
The data that support the findings of this study are available from HCHS/SOL but restrictions apply to the avail-
ability of these data, which were used under license for the current study, and so are not publicly available. Data 
are however available from the authors upon reasonable request and with permission of HCHS/SOL Steering 
Committee.
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